Article
Open Access
Volume 2 · Issue 4 · 2022
pp. 173–180
Relevancy of Serum SuPAR, PAI-1, MMP-9 Level, and Prognosis of Metastatic Colorectal Cancer During Diagnosis
Mehmet Eren Kalender1 
, Leyla Demir2 , Utku Oflazoglu1 , Yuksel Kucukzeybek1 , Tarik Salman1 , Umut Varol3 , Yasar Yildiz1 , Zeynep Sevgen Güç1 , Halil Taskaynatan4 , Ahmet Alacacıoglu1
, Leyla Demir2 , Utku Oflazoglu1 , Yuksel Kucukzeybek1 , Tarik Salman1 , Umut Varol3 , Yasar Yildiz1 , Zeynep Sevgen Güç1 , Halil Taskaynatan4 , Ahmet Alacacıoglu1
1
Department of Medical Oncology, Izmir Katip Celebi University, Izmir, Türkiye
2
Department of Biochemistry, Izmir Katip Celebi University, Izmir, Türkiye
3
Department of Medical Oncology, Izmir Demokrasi University, Izmir, Türkiye
4
Department of Medical Oncology, İzmir Özel Ege Şehir Hastanesi, Izmir, Türkiye
Abstract
Objectives: Serum suPAR, PAI-1, and MMP-9 biomarkers have been associated with the progression of the disease in many cancers, including the CRC. It aimed to determine the relation of serum suPAR, PAI-1, and MMP-9 levels with the prognosis of the disease in patients with mCRC.
Methods: Nonmetastatic CRC patients who had not yet been treated with the oncology polyclinic in İKCU and blood samples were taken from the patients with metastatic CRC before and after treatment, and the obtained serum was preserved. PAI-1, suPAR, and MMP-9 levels were studied by ELISA. The results were used to establish the relation with prognosis.
Results: When the metastatic CRC and non-metastatic CRC were compared before treatment for biomarkers; PAI-1(p-value: 0.030), suPAR(p-value: 0.009) and MMP-9(p-value: 0.003) were found to be highly significant. PAI-1 (p-value: 0.003), suPAR (p-value: 0.007), and MMP-9 (p-value: 0.001) in the pretreatment metastatic group and the control group after the treatment were statistically significant. ROC was performed and cut-off values were determined as (pai: 71.4 ng/ ml; supar: 1.97 ng/ ml; mmp: 812.5 ng/ ml). PFS and OS were evaluated to the cut-offs of markers using the Kaplan-Meier method. Cut off values were significant in terms of PFS (pai p-value, 0.008; supar p-value 0.019, mmp p-value 0.017) and OS (pai p-value, 0.03; supar p-value 0.059, mmp p-value 0.081).
Conclusion: Serum PAI-1, suPAR, and MMP-9 levels reveal the prognosis of patients with metastatic CRC.
Methods: Nonmetastatic CRC patients who had not yet been treated with the oncology polyclinic in İKCU and blood samples were taken from the patients with metastatic CRC before and after treatment, and the obtained serum was preserved. PAI-1, suPAR, and MMP-9 levels were studied by ELISA. The results were used to establish the relation with prognosis.
Results: When the metastatic CRC and non-metastatic CRC were compared before treatment for biomarkers; PAI-1(p-value: 0.030), suPAR(p-value: 0.009) and MMP-9(p-value: 0.003) were found to be highly significant. PAI-1 (p-value: 0.003), suPAR (p-value: 0.007), and MMP-9 (p-value: 0.001) in the pretreatment metastatic group and the control group after the treatment were statistically significant. ROC was performed and cut-off values were determined as (pai: 71.4 ng/ ml; supar: 1.97 ng/ ml; mmp: 812.5 ng/ ml). PFS and OS were evaluated to the cut-offs of markers using the Kaplan-Meier method. Cut off values were significant in terms of PFS (pai p-value, 0.008; supar p-value 0.019, mmp p-value 0.017) and OS (pai p-value, 0.03; supar p-value 0.059, mmp p-value 0.081).
Conclusion: Serum PAI-1, suPAR, and MMP-9 levels reveal the prognosis of patients with metastatic CRC.
Keywords: PAI-1, suPAR, and MMP-9, metastatic colorectal cancer
Current Issue Vol 2 · Iss 4
